1877.HK
JUNSHI BIO
HK$19.35
-8.12%
2026-06-01
About JUNSHI BIO
Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in China. The company's product pipelines include Tifcemalimab, an anti- B and T lymphocyte attenuator mAB which is in phase III clinical trial to treat lung cancer and lymphocyte; Roconkibart, an anti-interleukin-17A monoclonal antibody which is in phase III clinical trial to treat psoriatic and spondylitis; JS001sc, a subcutaneous injection which is in phase III clinical trial for the treatment of tumors; JS105, an oral small molecule inhibitor targeting PI3K-a which is in phase III clinical trial to treat gynecological tumors; and JS107, an antibody-drug conjugate which is in phase III clinical trial for the treatment of gastrointestinal cancer. It also develops JS212, JS213, JS207, JS203, JS125, JS214, and JS214 which is in phase I/II clinical trial for the treatment of tumors; JS111, a small molecule inhibitor targeting which is in phase I/II clinical trial to treat NSCLC; JS110, a small molecule inhibitor of the nuclear export protein XPO1 which is in phase I/II clinical trial to treat endometrial cancer; JS007, a recombinant humanized anti-Cytotoxic T lymphocyte associated antigen-4 monoclonal antibody which is in phase I/II clinical trial to treat lung cancer and melanoma; and JT002, A small nucleic acid immunomodulator which is in phase I/II clinical trial for the treatment of seasonal allergic rhinitis. In addition, the company offers TUOYI/LOQTORZI/ZYTORVI for tumors; JUNMAIKANG for the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriasis, Crohn's disease, uveitis, polyarticular juvenile idiopathic arthritis, pediatric plaque psoriasis, and pediatric Crohn's disease; VV116/JT001, an oral nucleoside analog drug; and JUNSHIDA to treat hyperlipidemia. The company was founded in 2012 and is headquartered in Shanghai, People's Republic of China.
Key Fundamentals
Forward P/E
-65.55
EPS (TTM)
HK$-0.97
ROE
-13.5%
Revenue Growth (YoY)
45.1%
Profit Margin
-24.3%
Debt/Equity
98.12
Price/Book
3.17
Beta
0.61
Market Cap
HK$21.60B
Avg Volume (10D)
3.1M
Recent Breakout Signals
No recent breakout signals detected for 1877.HK.
Recent Price Range (60 Days)
60D High
HK$30.80
60D Low
HK$17.58
Avg Volume
4.2M
Latest Close
HK$19.35
Get breakout alerts for 1877.HK
Sign up for Breakout Scanner to receive daily notifications when 1877.HK triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial.
JUNSHI BIO (1877.HK) is listed on the Hong Kong Exchanges (HKEX). Breakout Scanner monitors 1877.HK daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. 1877.HK operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.